Loading clinical trials...
Loading clinical trials...
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This is an open-label, single arm, dose escalation study in patients with relapsed or refractory CLL. Treatment will be administered on an outpatient basis and all patients will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in combination with venetoclax. One treatment cycle is 4 weeks.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Investigational Site
Baltimore, Maryland, United States
Investigational Site
Charlotte, North Carolina, United States
Investigational Site
Houston, Texas, United States
Start Date
January 25, 2019
Primary Completion Date
November 15, 2022
Completion Date
April 27, 2023
Last Updated
January 25, 2024
5
ACTUAL participants
CYC065
DRUG
Venetoclax
DRUG
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
NCT04872621
NCT03206918
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01578707